山东地区HBV基因型分布及拉米夫定抗病毒治疗对基因分型的影响  

Distribution of HBV genotypes in Shandong province and it's relationship with the antiviral effect of lamivudine

作　　者：孙正伟[1] 王威[1] 孙向阳[1] 董振芳[1] 

机构地区：[1]济南山东省立医院病毒室,250021

出　　处：《中华实验和临床病毒学杂志》2006年第4期402-404,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的确定乙型肝炎病毒(HBV)基因型在山东地区的分布及拉米夫定抗病毒疗效的影响。方法采用PCR微板核酸分子杂交酶联显色技术,对临床服用拉米夫定一年的131例乙型肝炎患者血清中的HBV-DNA进行基因分型,与未服用拉米夫定组对照。结果治疗组C型为87.4%(90/103),D型为12.6%(13/103)。对照组C型为89.3%(25/28),D型为10.7%(3/28),两组间差异无统计学意义。均未发现A、B、E和F基因型。结论首次从临床慢性乙肝患者中得出山东地区HBV优势基因型为C基因型,同时存在D基因型。服用拉米夫定治疗一年对HBV基因型没有影响。Objective To ascertain the distribution of HBV genotypes in Shandong province and its relationship with the antiviral effect of lamivudine. Methods Totally 131 hepatitis B patients who have received lamivudine for 1 year were studied. PCR micro-plate nucleic acid hybridization-ELISA was used to determine their genotypes, and hepatitis B patients who did not take lamivudine served as controls. Results Of the 103 patients, 90（87.4% ） had genotype C and 13 （12.6%） had genotype D in the therapeutic group; 89.3 % （25/28） had genotype C and 10.7% （3/28） genotype D in the control group. Genotype A, B, E and F were not detected. Conclusions HBV genotype C is predominant in Shandong province, and genotype D was also discovered. There were no genotype changes in the patients who have taken the lamivudine for 1 year.

关 键 词：肝炎病毒 乙型 基因型 拉米夫定 核酸杂交 

分 类 号：R373[医药卫生—病原生物学] R512.62[医药卫生—基础医学]